The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Jonsson Comprehensive Cancer Center

ClinicalTrials.gov Identifier:

NCT01180868

First received: August 11, 2010

Last updated: July 27, 2012

Last verified: July 2012

History of Changes

Purpose

The purpose of this study is to determine the biodistribution of a new agent 1-L-(2 deoxy-2,-18fluoroarabinofuranosyl) cytosine non-invasively in healthy humans and to evaluate whether it can be used to image cancer, autoimmune disease, and inflammation

Condition
Autoimmune Diseases Cancer


Study Type:	Observational
Official Title:	The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases

Resource links provided by NLM:

MedlinePlus related topics: Autoimmune Diseases Cancer

U.S. FDA Resources

Further study details as provided by Jonsson Comprehensive Cancer Center:


Enrollment:	1
Study Start Date:	May 2008
Primary Completion Date:	November 2011 (Final data collection date for primary outcome measure)

Groups/Cohorts
patients with cancer patients with hematological malignancies and solid tumors
patients with autoimmune dosorders patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.
healthy subjects

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Patients with cancer, patients with autoimmune dosorders, and healthy subjects.

Criteria

Inclusion Criteria:

greater than 18 years of age
women of childbearing potential will undergo a pregnancy test free of charge
patients with hematological malignancies, solid tumors or autoimmune disorders

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01180868

Locations


United States, California
UCLA
Los Angeles, California, United States, 90095

Sponsors and Collaborators

Jonsson Comprehensive Cancer Center

Investigators


Principal Investigator:	Christiaan Schiepers, M.D. Ph.D	University of California, Los Angeles

More Information

No publications provided


Responsible Party:	Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:	NCT01180868 History of Changes
Other Study ID Numbers:	08-02-049, DE-PS02-08ER08-01, CIRM No. RT1-01126-1
Study First Received:	August 11, 2010
Last Updated:	July 27, 2012
Health Authority:	United States: Institutional Review Board

Keywords provided by Jonsson Comprehensive Cancer Center:


imaging probe cancer inflammatory tissue inflammatory diseases

Additional relevant MeSH terms:


Autoimmune Diseases Immune System Diseases

ClinicalTrials.gov processed this record on March 03, 2015

To Top